🏛️ Verified NIH Record • Updated 2026-06-02
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (NCT06557265)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Nkarta, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
Who can join: Review the eligibility criteria below.
Location: Nkarta Investigational Site — Little Rock, Arkansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Nkarta Investigational Site — Little Rock, Arkansas
- Nkarta Investigational Site — Tustin, California
- Nkarta Investigational Site — Gainesville, Florida
- Nkarta Investigational Site — Miami, Florida
- Nkarta Investigational Site — Plantation, Florida
- Nkarta Investigational Site — Tampa, Florida
- Nkarta Investigational Site — Atlanta, Georgia
- Nkarta Investigational Site — Chicago, Illinois
- Nkarta Investigational Site — New Orleans, Louisiana
- Nkarta Investigational Site — Worcester, Massachusetts
- Nkarta Investigational Site — Ann Arbor, Michigan
- Nkarta Investigational Site — Summit, New Jersey
- Nkarta Investigational Site — New York, New York
- Nkarta Investigational Site — Stony Brook, New York
- Nkarta Investigational Site — Syracuse, New York
- Nkarta Investigational Site — Dallas, Texas
- Nkarta Investigational Site — Houston, Texas
- Nkarta Investigational Site — Parkville, Victoria
- Nkarta Investigational Site — Manati,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Nephritis
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis — Palo Alto, California
- Daratumumab to Treat Active Lupus Nephritis — Rochester, Minnesota
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Birmingham, Alabama
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis — Glendale, Arizona
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases — Phoenix, Arizona
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis — Birmingham, Alabama
Explore by condition: All Lupus Nephritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.